A large study in older adults with type 2 diabetes finds that GLP-1 receptor agonists are associated with a modestly ...

The company’s health services division Evernorth is doubling down on a reliable growth area: assuaging payer concerns around ...

Cigna (CI) unveils ENGUIDE, a specialized GLP-1 pharmacy to be launched next month as demand for obesity drugs like Wegovy ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...

Proportion of adult managed care organizations with availability varied from 24 to 100 percent for SGLT2 inhibitors, 0 to 99 percent for GLP-1 receptor agonists.

Obesity can lead to a chronic inflammatory state within the body. What drives this inflammation? Does inflammation, in turn, ...

Ebn Sina Medical, a subsidiary of Aamal Company, and Danish healthcare major Novo Nordisk have launched the weight loss ...

Doha: Ebn Sina Medical, a subsidiary of Aamal Company Q.P.S.C. and a leading supplier of pharmaceutical, and Novo Nordisk, ...

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.

There is a low incidence rate of suicide-related adverse events among adults with diabetes or obesity being treated with GLP-1 RAs.